Avenus announced new oculomotor function and biomarker data for the phase 1 clinical trial of ARV-102, its Parkinson's disease treatment drug.

Zhitongcaijing · 2d ago
Avenus announced new oculomotor function and biomarker data for the phase 1 clinical trial of ARV-102, its Parkinson's disease treatment drug.